Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CGTX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) NCT05637801 · Alzheimer Disease, Alzheimer Disease 1 Spectris™ AD - Active, Spectris™ AD - Sham | CGTX Cognito Therapeutics, Inc. | Not applicable | Completed | 673 | Jun 22, 2026 | Registry ↗ |
| Aug 10, 2026 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease NCT05531656 · Early Alzheimer's Disease CT1812, Placebo | CGTX Cognition Therapeutics | Phase 2 | Active, not recruiting | 540 | May 31, 2027 | Registry ↗ |
| May 28, 2026 | Expanded Access Program for CT1812 (Zervimesine) NCT06961760 · Dementia With Lewy Bodies zervimesine | CGTX Cognition Therapeutics | — | No longer available | — | — | Registry ↗ |
| Mar 12, 2026 | Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate… NCT05225415 · Dementia With Lewy Bodies CT1812 | CGTX Cognition Therapeutics | Phase 2 | Completed | 130 | Nov 25, 2024 | Registry ↗ |
| Aug 11, 2025 | A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's… NCT03507790 · Mild to Moderate Alzheimer's Disease CT1812, Placebo | CGTX Cognition Therapeutics | Phase 2 | Completed | 153 | May 29, 2024 | Registry ↗ |
| Apr 16, 2025 | Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (G… NCT05893537 · Age-Related Macular Degeneration Active Comparator CT1812, Placebo Comparator | CGTX Cognition Therapeutics | Phase 2 | Terminated | 100 | Mar 4, 2025 | Registry ↗ |
| Nov 29, 2024 | Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG NCT04735536 · Alzheimer Disease CT1812, Placebo | CGTX Cognition Therapeutics | Phase 2 | Completed | 16 | Apr 26, 2023 | Registry ↗ |
| May 7, 2024 | Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) NCT06245031 · Alzheimer Disease, Cognitive Impairment Sensory Stimulation System (GS120) - Active | CGTX Cognito Therapeutics, Inc. | Not applicable | Enrolling by invitation | 402 | Dec 2026 | Registry ↗ |
| Sep 7, 2023 | Effect of CT1812 Treatment on Brain Synaptic Density NCT03493282 · Alzheimer Disease Active Treatment- CT1812 100 mg, Active Treatment- CT1812 3… | CGTX Cognition Therapeutics | Phase 1/2 | Completed | 43 | Oct 16, 2020 | Registry ↗ |
| Jul 21, 2023 | Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult… NCT05225389 · Alzheimer Disease 300 mg [C14] CT1812 | CGTX Cognition Therapeutics | Phase 1 | Completed | 8 | Jan 17, 2022 | Registry ↗ |
| Apr 12, 2023 | Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers NCT05248672 · Alzheimer Disease CT1812 | CGTX Cognition Therapeutics | Phase 1 | Completed | 35 | Jun 1, 2022 | Registry ↗ |
| Jan 12, 2022 | Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in… NCT03522129 · Alzheimer Disease CT1812, Placebo | CGTX Cognition Therapeutics | Phase 1 | Completed | 3 | Feb 6, 2019 | Registry ↗ |
| Aug 24, 2021 | Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improv… NCT03661034 · Alzheimer Disease, Early Onset, Alzheimer Disease GammaSense Stimulation System (non-invasive, non-significan… | CGTX Cognito Therapeutics, Inc. | Not applicable | Unknown | 20 | May 1, 2021 | Registry ↗ |
| Aug 24, 2021 | Multi-Center Study of Sensory Stimulation to Improve Brain Function NCT03556280 · Alzheimer Disease, Cognitive Impairment GammaSense Stimulation System (Active Settings), GammaSense… | CGTX Cognito Therapeutics, Inc. | Not applicable | Active, not recruiting | 60 | Aug 1, 2020 | Registry ↗ |
| Oct 23, 2018 | Drug Interaction Study of CT1812 in Healthy Volunteers NCT03716427 · Healthy Volunteers CT1812, tolbutamide | CGTX Cognition Therapeutics | Phase 1 | Completed | 16 | Dec 27, 2016 | Registry ↗ |
| Jul 26, 2018 | Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease NCT02907567 · Alzheimer's Disease CT1812, Placebo | CGTX Cognition Therapeutics | Phase 1/2 | Completed | 19 | Aug 24, 2017 | Registry ↗ |
| Sep 7, 2016 | Ascending Dose Study of CT1812 in Healthy Volunteers NCT02570997 · Cognitive Impairment CT1812, Placebo | CGTX Cognition Therapeutics | Phase 1 | Completed | 80 | May 2016 | Registry ↗ |
17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances